Last update: Feb. 11, 2020
Moderately safe. Probably compatible.
Mild risk possible. Follow up recommended.
Read the Comment.
A sympathomimetic with alpha-adrenergic activity. It has a vasoconstrictor effect that reduces mucosal swelling and congestion.
Topical nasal use or ophthalmological (2-3 times a day).
Since the last update we have not found published data in relation to breastfeeding.
The small dose and the low plasma absorption of most topical nasal or ophthalmological preparations make transfer into breastmilk in significant amounts unlikely.
Do not exceed the recommended dose and time periods in order to avoid undesirable side effects and the possible decrease in milk cited by some authors (Nice 2000) for other similar drugs, although not proven in practice.
It is a product which has very little literature and almost none related to pharmacokinetics.
As a nasal decongestant, it is discouraged by some authors (Nice 2000), with better known drugs from the same group being preferred (Anderson 2000).
Ophthalmic administration is fully compatible with breastfeeding. Absorption can be minimized by pressing on the tear duct (medial canthus of the eye) with your finger for 1 minute.
Some authors consider decongestant drugs administered orally and nasally to be non-essential medications, to be avoided in general, not only during breastfeeding, since they expose patients to serious risks (cardiovascular, neurological and intestinal) for the treatment of benign disorders such as nasal obstruction, which usually evolves favourably in a few days without medication (Prescrire 2018).
Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.